poisar

Stocks · News reference

Daiwa Capital Upgrades Merck & Co to Outperform, Raises Price Target to $143

Aug 12, 2026, 3:48 PMBenzinga Newsdesk

Daiwa Capital analyst Narumi Nakagiri upgrades Merck & Co (NYSE:MRK) from Neutral to Outperform and raises the price target from $120 to $143.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

MRK
Source
benzinga
Observed
Aug 12, 2026, 3:48 PM
Checked
Aug 12, 2026, 3:48 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 4:11 PMNa

    SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

    Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

    Read original at zacks-investment-research
    SMMTAZNMRK